TacticScaleWhat BioMarin Pharmaceutical Does & How It Makes Money (BMRN)
Updated October 2026 · reflects BioMarin Pharmaceutical's latest reported financials
Biotech company making therapies for rare genetic diseases. BioMarin earns revenue by selling its specialty rare-disease drugs to specialty pharmacies, hospitals, non-U.S.
How BioMarin Pharmaceutical makes money
BioMarin earns revenue by selling its specialty rare-disease drugs to specialty pharmacies, hospitals, non-U.S. government agencies, distributors and wholesalers. It also has license and collaboration agreements, including one with Ares Trading S.A.
What BioMarin Pharmaceutical does
BioMarin Pharmaceutical, founded in 1996 and based in San Rafael, California, focuses on therapies for rare, life-threatening genetic diseases. Many of its products are enzyme replacement therapies for lysosomal storage disorders: VIMIZIM for MPS IVA, NAGLAZYME for MPS VI, ALDURAZYME (alpha-L-iduronidase) and BRINEURA for CLN2 Batten disease. VOXZOGO, a once-daily CNP analog injection, treats achondroplasia. PALYNZIQ and KUVAN are its phenylketonuria (PKU) treatments. Its development pipeline includes BMN 333, a longer-acting CNP for achondroplasia, hypochondroplasia and other growth disorders, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy. The company sells its drugs worldwide through specialty pharmacies, hospitals, government agencies, distributors and wholesalers, and it also has licensing and collaboration agreements.
Products & services
- VOXZOGO (achondroplasia)
- VIMIZIM (MPS IVA)
- NAGLAZYME (MPS VI)
- PALYNZIQ (PKU)
- BRINEURA (CLN2 Batten disease)
- KUVAN (PKU)
What is BioMarin Pharmaceutical worth?
On an owner-earnings DCF, BioMarin Pharmaceutical's most-likely value is about $95 versus a recent price near $55 (73% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$40) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Biogen (BIIB) · Sarepta Therapeutics (SRPT) · PTC Therapeutics (PTCT) · Bristol-Myers Squibb (BMY)